Rapid Point-of-Care Testing for Sickle Cell Anemia Market Summary

The global rapid point-of-care testing for sickle cell anemia market size was estimated at USD 304.83 million in 2024 and is projected to reach USD 522.83 million by 2030, growing at a CAGR of 9.7% from 2025 to 2030. This growth is primarily driven by continuous advancements in diagnostic technologies and a rising global demand for accessible, fast, and reliable healthcare solutions. As early detection becomes increasingly important in managing chronic genetic disorders like sickle cell anemia, point-of-care (POC) testing is emerging as a key tool in improving clinical outcomes and expanding diagnostic reach.

POC tests offer rapid, accurate, and cost-effective diagnosis, making them especially valuable in resource-limited regions where the burden of sickle cell disease (SCD) is highest. Their portability and ease of use allow healthcare providers to identify affected individuals quickly, enabling timely intervention and reducing morbidity. Alongside technological innovation, growing investments and collaborations with global health organizations are strengthening the availability and affordability of these tests. Expanding healthcare infrastructure in developing nations is further supporting market growth. According to an August 2023 report by ScienceDirect, between 2000 and 2021, the national incidence rate of SCD remained stable, yet the total number of global births with the condition increased by 13.7%, reaching 515,000. This surge is largely attributed to population growth in regions such as the Caribbean and western and central sub-Saharan Africa, where the demand for rapid testing continues to rise.

Key Market Trends & Insights

• North America dominated the rapid point-of-care testing for sickle cell anemia market and accounted for a 43.97% share in 2024, supported by advanced diagnostics infrastructure, strong healthcare funding, and high adoption rates of innovative testing solutions.
• Asia Pacific is anticipated to witness significant growth over the forecast period, driven by increasing awareness, rising diagnostic needs, and expanding public health initiatives.
• Based on end use, the hospitals and clinics segment accounted for the largest revenue share in 2024, reflecting their critical role in early diagnosis, treatment planning, and ongoing patient monitoring.
• In terms of distribution channel, the B2B segment dominated the industry in 2024, due to bulk procurement by hospitals, laboratories, NGOs, and government programs focused on screening large populations.
• Based on type, lateral flow immunoassay held the largest revenue share of 51.66% in 2024, owing to its simplicity, rapid results, and suitability for use in low-resource settings.

Order a free sample PDF of the Rapid Point-of-Care Testing for Sickle Cell Anemia Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 304.83 Billion
• 2030 Projected Market Size: USD 522.83 Billion
• CAGR (2025-2030): 9.7%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some of the key players operating in the rapid point-of-care testing for sickle cell anemia market include BioMedomics Inc.; Silver Lake Research Corporation; Bio-Rad Laboratories, Inc.; Trivitron Healthcare; Hemex Health; Sysmex Corporation; EKF Diagnostics Holdings plc; and HemoCue America (Danaher Corporation). These established companies are driving innovation through robust R&D capabilities, portable diagnostic platforms, and user-friendly rapid test kits that enable early and accurate detection of sickle cell disease. Their strategies are centered around continuous product development, geographic expansion, and strategic collaborations with healthcare providers and public health programs to improve accessibility in high-prevalence regions.

Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease.

Key Players

• BIOMEDOMICS INC.
• Silver Lake Research Corporation
• Bio-Rad Laboratories, Inc.
• Trivitron Healthcare
• Hemex Health
• Sysmex Corporation
• EKF Diagnostics Holdings plc.
• HemoCue America (Danaher)

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

In conclusion, the rapid point-of-care testing market for sickle cell anemia is poised for strong growth as demand for accessible and timely diagnostics continues to rise worldwide. Technological advancements, expanding healthcare infrastructure, and increasing global awareness of early detection are driving widespread adoption of portable testing solutions. The growing number of births affected by SCD, particularly in high-prevalence regions, further underscores the need for efficient screening tools. With strong contributions from hospitals, clinics, and large-scale B2B procurement channels, the industry is expected to accelerate through 2030, supporting improved disease management and better health outcomes for vulnerable populations.